Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Breast CancerHead and Neck CancerDiffuse Large B-cell Lymphoma
Interventions
RADIATION

PET/CT

Patients receive F-18-ISO-1 i.v. and undergo PET/CT imaging at 2-3 time points following the injection.

OTHER

Laboratory Testing

Blood and urine samples for laboratory analysis and radioactive counts will be obtained during the imaging sessions

OTHER

Safety Testing

ECG tracings, and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during, and after the imaging sessions.

OTHER

Immunohistochemistry staining

If available tissue from a biopsy or surgery will be tested cellular proliferation markers such as Ki67 and sigma 2 receptors

DRUG

F-18-ISO

Patients receive F-18-ISO-1 i.v.

Trial Locations (1)

63110

Washington University / Barnes Jewish Hospital, St Louis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Isotrace Technologies

UNKNOWN

lead

Washington University School of Medicine

OTHER

NCT00968656 - Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1 | Biotech Hunter | Biotech Hunter